 Neoplasm, Residual
"Neoplasm, Residual" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
| Descriptor ID |
D018365
|
| MeSH Number(s) |
C04.697.700 C23.550.727.700
|
| Concept/Terms |
Neoplasm, Residual- Neoplasm, Residual
- Residual Disease, Minimal
- Disease, Minimal Residual
- Diseases, Minimal Residual
- Minimal Residual Diseases
- Residual Diseases, Minimal
- Residual Neoplasm
- Neoplasms, Residual
- Residual Neoplasms
- Minimal Disease, Residual
- Disease, Residual Minimal
- Diseases, Residual Minimal
- Minimal Diseases, Residual
- Residual Minimal Disease
- Residual Minimal Diseases
- Minimal Residual Disease
Residual Cancer- Residual Cancer
- Cancer, Residual
- Cancers, Residual
- Residual Cancers
Residual Tumor- Residual Tumor
- Residual Tumors
- Tumor, Residual
- Tumors, Residual
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm, Residual".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm, Residual".
This graph shows the total number of publications written about "Neoplasm, Residual" by people in this website by year, and whether "Neoplasm, Residual" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 2 | 3 | | 1997 | 0 | 2 | 2 | | 1999 | 0 | 4 | 4 | | 2000 | 0 | 2 | 2 | | 2001 | 1 | 2 | 3 | | 2002 | 0 | 1 | 1 | | 2003 | 2 | 1 | 3 | | 2004 | 0 | 2 | 2 | | 2005 | 2 | 1 | 3 | | 2006 | 0 | 3 | 3 | | 2007 | 2 | 0 | 2 | | 2008 | 1 | 2 | 3 | | 2009 | 0 | 1 | 1 | | 2010 | 1 | 2 | 3 | | 2011 | 1 | 3 | 4 | | 2012 | 0 | 8 | 8 | | 2013 | 1 | 4 | 5 | | 2014 | 0 | 1 | 1 | | 2015 | 1 | 5 | 6 | | 2016 | 3 | 4 | 7 | | 2017 | 1 | 6 | 7 | | 2018 | 1 | 2 | 3 | | 2019 | 4 | 4 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoplasm, Residual" by people in Profiles.
-
Ritterhouse LL, Parilla M, Zhen CJ, Wurst MN, Puranik R, Henderson CM, Joudeh NZ, Hartley MJ, Haridas R, Wanjari P, Furtado LV, Kadri S, Segal JP. Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing. Mol Diagn Ther. 2019 12; 23(6):791-802.
-
Jabbour E, Gökbuget N, Advani A, Stelljes M, Stock W, Liedtke M, Martinelli G, O'Brien S, Wang T, Laird AD, Vandendries E, Neuhof A, Nguyen K, Dakappagari N, DeAngelo DJ, Kantarjian H. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leuk Res. 2020 01; 88:106283.
-
Balagopal V, Hantel A, Kadri S, Steinhardt G, Zhen CJ, Kang W, Wanjari P, Ritterhouse LL, Stock W, Segal JP. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing. PLoS One. 2019; 14(10):e0224097.
-
Pianko MJ, Devlin SM, Littmann ER, Chansakul A, Mastey D, Salcedo M, Fontana E, Ling L, Tavitian E, Slingerland JB, Slingerland AE, Clurman A, Gomes ALC, Taur Y, Pamer EG, Peled JU, van den Brink MRM, Landgren O, Lesokhin AM. Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition. Blood Adv. 2019 07 09; 3(13):2040-2044.
-
Patel SS, Pinkus GS, Ritterhouse LL, Segal JP, Dal Cin P, Restrepo T, Harris MH, Stone RM, Hasserjian RP, Weinberg OK. High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia. Am J Hematol. 2019 08; 94(8):921-928.
-
Stein JE, Soni A, Danilova L, Cottrell TR, Gajewski TF, Hodi FS, Bhatia S, Urba WJ, Sharfman WH, Wind-Rotolo M, Edwards R, Lipson EJ, Taube JM. Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response. Ann Oncol. 2019 04 01; 30(4):589-596.
-
Curran E, Stock W. Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL. Blood. 2019 04 18; 133(16):1715-1719.
-
McNeer JL, Devidas M, Dai Y, Carroll AJ, Heerema NA, Gastier-Foster JM, Kahwash SB, Borowitz MJ, Wood BL, Larsen E, Maloney KW, Mattano L, Winick NJ, Schultz KR, Hunger SP, Carroll WL, Loh ML, Raetz EA. Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group. J Clin Oncol. 2019 04 01; 37(10):780-789.
-
Westin C, Chatterjee A, Ku E, Yousuf A, Wang S, Thomas S, Fan X, Eggener S, Karczmar G, Oto A. MRI Findings After MRI-Guided Focal Laser Ablation of Prostate Cancer. AJR Am J Roentgenol. 2018 09; 211(3):595-604.
-
Hantel A, Stock W, Kosuri S. Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):636-647.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|